We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Proteros Biostructures and Boehringer Ingelheim Enter into Protein Crystallography Agreement
News

Proteros Biostructures and Boehringer Ingelheim Enter into Protein Crystallography Agreement

Proteros Biostructures and Boehringer Ingelheim Enter into Protein Crystallography Agreement
News

Proteros Biostructures and Boehringer Ingelheim Enter into Protein Crystallography Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Proteros Biostructures and Boehringer Ingelheim Enter into Protein Crystallography Agreement "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Proteros biostructures GmbH has announced that it has entered into a research collaboration with Boehringer Ingelheim Pharmaceuticals, Inc. in the field of protein crystallography.

Under the terms of the agreement, which will run for 18 months, Proteros will receive research funding fees and success payments for the generation and analyzes of protein-ligand-structures of hits and evolved chemical entities from in-house Boehringer Ingelheim programs.

Proteros will apply its proprietary Free Mounting System (FMS™) and Picodropper™ technologies to maximize data quality and success rates, thus allowing rapid evolution of multiple hit series at Boehringer Ingelheim.

Financial details of the transaction were not disclosed.

Torsten Neuefeind, Ph.D., Chief Executive Officer of Proteros, stated, ”We are pleased to extend the scope of our long standing relationship with various sites of Boehringer Ingelheim. By taking advantage of Proteros’ experience and the industrialized processes enabling time- and cost-efficient protein-ligand-structure analyses, Boehringer Ingelheim complements its internal capabilities with our external expertise and access flexible resources. Especially when working with challenging chemical entities, Proteros’ Picodropper™ can make the difference between success and failure.”

Mr. Neuefeind continued: “This collaboration underscores Proteros’ expertise in the field of protein crystallography, and furthermore marks an important milestone in Proteros’ progress to further expand its client base in North America.”

Advertisement